Adagene Inc. ADAG
Set alert
2.51 USD -0.17 -6.34%
At close · Oct 30
2.51 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
2.46 Day range 2.69
1.30 52-week range 4.85
- YTD
- +32.80%
- 1 year
- +30.73%
- Open
- 2.67
- Prev close
- 2.68
- Mkt cap
- 168.53M
- Vol
- 79.69K
- Avg vol
- 279.93K
- EPS
- -0.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.46
- High
- 2.69
- Forward P/E
- -2.81
- Beta
- 0.58
- Short ratio
- 0.66
- Inst. own
- 25.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 2, 2024
- 50-d avg
- 2.44
- 200-d avg
- 2.59
- 1y target
- 8.03
News
-
4 days ago benzinga.com
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
4 days ago globenewswire.com
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte's TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
5 days ago globenewswire.com
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…